"Although Lahti is an investor who thinks with logic rather than emotion, his portfolio also contains ‘hope’ stocks that cannot be justified by logic.
‘I have room in my portfolio, and I want Finnish companies like Faron and Nanoform to make a big breakthrough. I want to be involved in supporting them.’"
Will we finally move from “hope” status closer to a rational choice after Q2? It will be exciting to see the impact of the €1 million bio-licensing agreement and, above all, the effectiveness of the cost-saving program on the results.
And hopefully, we will hear something new about the situation with enzalutamide.
The expectant atmosphere seems to have been reflected in the trading volume, and holdings have also remained almost unchanged.